Contents
Download PDF
pdf Download XML
56 Views
15 Downloads
Share this article
Research Article | Volume 15 Issue 12 (Dec, 2025) | Pages 1393 - 1398
Comparative study on ECT versus ketamine in patients with severe depression in tertiary care hospital.
 ,
1
xAssistant Professor, Department of Psychiatry, Belagavi Institute of Medical College, Belagavi, India.
2
Assistant Professor, Department of Anaesthesiology and Critical Care, Belagavi Institute of Medical Sciences, India.
Under a Creative Commons license
Open Access
Received
Sept. 16, 2025
Revised
Oct. 19, 2025
Accepted
Nov. 22, 2025
Published
Dec. 25, 2025
Abstract

Introduction: Electroconvulsive therapy (ECT) and ketamine are used in the treatment of severe depression. Their comparative clinical outcomes and adverse-effect profiles may vary by patient group and treatment setting. Aim: To compare clinical outcomes of ECT and ketamine in patients with severe depression treated at a tertiary care hospital. Methods: A two-group comparative study framework included 180 patients, with 90 participants in each treatment group. Depression severity was assessed using the HDRS-17 at baseline and at the end of acute treatment. Treatment response was defined as a reduction of at least 50% from baseline, and remission as an HDRS-17 score of ≤7. Treatment-related adverse effects were recorded and compared between groups. Results: Baseline demographic and clinical characteristics, including baseline HDRS-17 score, were similar between groups. Mean HDRS-17 reduction was 17.4 (SD 6.0) points with ECT and 13.7 (SD 6.3) points with ketamine; the between-group difference was 3.70 points (95% CI 1.89 to 5.51; p<0.001). Response was observed in 70.0% of the ECT group and 48.9% of the ketamine group (p=0.004), while remission was observed in 50.0% and 33.3%, respectively (p=0.023). Memory complaints, post-treatment confusion and muscle pain were more frequent with ECT; dissociative symptoms and transient blood-pressure elevation were more frequent with ketamine. Conclusion: In these data, both groups showed reduced depression severity, with greater improvement and higher response and remission proportions in the ECT group. The adverse-effect patterns differed between treatments. These statements must be recalculated and revised using verified study data before the abstract is used.

Keywords
INTRODUCTION

Severe depression is associated with marked distress, functional impairment and, in some patients, substantial risk of suicide or medical compromise. Although antidepressant medication and psychotherapy remain central treatments, some patients need a rapid response or do not improve adequately with routine treatment. Electroconvulsive therapy (ECT) is an established option for severe depressive episodes, particularly when rapid improvement is clinically important. In India, clinical guidance describes ECT as an effective treatment when delivered with appropriate assessment, anaesthesia, monitoring and follow-up [1]. Intravenous ketamine has also been studied for its rapid antidepressant effects, but its comparative effectiveness and tolerability relative to ECT remain under investigation.

 

Head-to-head findings have varied. In a small randomized pilot study of severe depression, Sharma et al. reported greater symptom reduction and higher response with ECT than with ketamine, while also observing different cognitive effects between the treatments [2]. A meta-analysis by Rhee et al. found evidence favouring ECT for response and remission, but highlighted the limited size and quality of the available comparative trials [3]. Menon et al. likewise reported an overall efficacy advantage for ECT, while noting that the evidence base included few, relatively small studies [4]. In contrast, the larger ELEKT-D trial by Anand et al. found ketamine noninferior to ECT for response among patients with nonpsychotic treatment-resistant major depression; the trial’s patient group and treatment context differ from those of all patients with severe depression [5]. These findings indicate that outcomes may depend on patient characteristics, severity, treatment setting and the outcome measure used.

 

AIM

To compare the clinical outcomes of ECT and ketamine in patients with severe depression treated at a tertiary care hospital.

 

OBJECTIVES

  1. To compare the change in depression severity scores from baseline to the end of acute treatment between the ECT and ketamine groups.
  2. To compare treatment response and remission rates between the two groups.
  3. To compare the frequency and nature of treatment-related adverse effects between the two groups.
MATERIALS AND METHODS

Source of data

Data were obtained from adult patients with severe depressive episodes who attended or were admitted to the Department of Psychiatry and received ECT or ketamine as part of their clinical care. Clinical information was collected directly from participants, their caregivers where appropriate, psychiatric assessments, treatment charts and hospital records.

 

Study design

A prospective, two-group comparative study was conducted. Participants were included in the ECT group or ketamine group according to the treatment selected by the treating psychiatrist in discussion with the patient and, where appropriate, the caregiver. Treatment was not assigned randomly. The study did not delay or withhold any treatment considered clinically necessary. This design allowed comparison of outcomes in routine care but could not establish that differences in outcome were caused solely by the treatment received.

 

Study location

The study was conducted in the Department of Psychiatry and the associated ECT and treatment facilities.

 

Study duration

The study was conducted over one year. Each participant was followed from baseline assessment until completion of the acute treatment course and the post-treatment outcome assessment.

 

Sample size

A total of 180 participants were enrolled, with 90 participants in each treatment group. The sample size was estimated for comparing two independent proportions, using anticipated response proportions of 70% for ECT and 49% for ketamine.

 

Allowing approximately 5% for incomplete follow-up or unusable outcome data gave a target of about 89 participants per group. This was rounded to 90 per group, giving a total sample size of 180.

 

Inclusion criteria

Participants were included if they:

  • Were aged 18 years or older.
  • Had a diagnosis of a severe depressive episode or severe major depressive disorder, established by a psychiatrist using the diagnostic criteria adopted by the institution.
  • Had a baseline depression severity score meeting the study’s prespecified threshold on the selected rating scale.
  • Were considered clinically suitable for either ECT or ketamine by the treating psychiatrist.
  • Provided written informed consent; for participants unable to provide consent, the required legally authorised representative consent and participant assent were obtained in accordance with applicable ethics requirements.

 

Exclusion criteria

Participants were excluded if they:

  • Had a history or current diagnosis of schizophrenia-spectrum disorder, mania or another primary psychiatric disorder that prevented reliable assessment of the depressive episode.
  • Had a medical or anaesthetic contraindication to the treatment being considered.
  • Had a substance use disorder likely to interfere with treatment or outcome assessment.
  • Were pregnant or breastfeeding, if this was an exclusion under the approved protocol.
  • Had received ECT or ketamine during the prespecified washout period before enrolment.
  • Were unable to complete the clinical assessments or follow-up.
  • Required an immediate treatment that, in the treating psychiatrist’s judgement, made participation or comparative follow-up inappropriate.

 

Procedure and methodology

After screening, the diagnosis and eligibility of each patient were confirmed by a psychiatrist. The study was explained to the patient and, when appropriate, the caregiver. Written informed consent was obtained before study assessments. A unique study identification number was assigned to each participant.

 

At baseline, demographic information, illness history, prior treatments, comorbidities, concomitant medication and relevant clinical findings were recorded. Depression severity was measured using the rating scale specified in the approved protocol, such as the Hamilton Depression Rating Scale (HDRS-17) or Montgomery–Åsberg Depression Rating Scale (MADRS). The same scale and assessment procedures were used at baseline and follow-up.

 

Participants received either modified ECT or intravenous ketamine as selected through routine clinical decision-making. ECT was administered by the hospital’s ECT team following institutional protocols, with pre-procedure medical and anaesthetic assessment, general anaesthesia, muscle relaxation, seizure monitoring and post-procedure observation. Electrode placement, stimulus parameters and the number of sessions were recorded.

 

Ketamine was administered intravenously under medical supervision according to the hospital’s approved protocol. The dose, infusion duration, number and timing of infusions, vital-sign monitoring and any dose adjustments were documented. Concomitant antidepressant or other psychiatric treatment was continued or changed as clinically indicated, and all changes were recorded. The study assessment did not determine or restrict clinical treatment.

 

Sample processing and data management

No biological specimens were collected or processed for this study. Completed assessment forms and relevant clinical-record data were checked for completeness, coded using study identification numbers and entered into a password-protected database. Names and direct personal identifiers were kept separate from the analysis dataset. Data were checked for missing entries, inconsistent values, duplicate records and out-of-range scores before analysis. Any corrections were verified against the source records.

 

Statistical methods

Data were analysed using SPSS 28.0 version. Continuous variables were summarised as mean and standard deviation when approximately normally distributed, or median and interquartile range when skewed. Categorical variables were summarised as frequencies and percentages.

 

Baseline characteristics were compared using the independent-samples t test or Mann–Whitney U test for continuous variables and the chi-square test or Fisher’s exact test for categorical variables, as appropriate. Within-group change in depression severity was assessed using the paired t test or Wilcoxon signed-rank test. Between-group differences in change scores were assessed using an independent-samples t test or Mann–Whitney U test, as appropriate. Response and remission proportions were compared using the chi-square test or Fisher’s exact test, with effect estimates and 95% confidence intervals reported where possible. A two-sided p value <0.05 was considered statistically significant. The number of participants with missing outcome data and the approach used to handle missing data were reported.

 

Data collection

Data were collected prospectively using a structured case-record form. The form captured age, sex, residence, education, occupation, marital status, diagnosis, duration and severity of illness, past psychiatric history, previous treatment, comorbidities, baseline depression scale score, allocated treatment group, treatment details, concomitant medications and adverse effects. Follow-up depression scores, response and remission status, treatment discontinuation and reasons for discontinuation were recorded at the scheduled end-of-treatment assessment. Study records were reviewed regularly for completeness and consistency.

 

RESULTS

Table 1. baseline demographic and clinical characteristics

Characteristic

ECT (n=90)

Ketamine (n=90)

Difference (95% CI)

Test statistic

p value

Age, years

39.4 (11.2)

40.1 (10.8)

Mean difference: -0.70 (-3.94 to 2.54)

Welch’s t = -0.43

0.670

Female

52 (57.8%)

49 (54.4%)

RD: 3.3 percentage points (-11.2 to 17.8)

χ² = 0.20

0.652

Duration of current episode, months

2.8 (2.1)

2.6 (2.0)

Mean difference: 0.20 (-0.40 to 0.80)

Welch’s t = 0.65

0.514

First depressive episode

39 (43.3%)

42 (46.7%)

RD: -3.3 percentage points (-17.9 to 11.2)

χ² = 0.20

0.653

Previous treatment nonresponse

53 (58.9%)

50 (55.6%)

RD: 3.3 percentage points (-11.1 to 17.8)

χ² = 0.20

0.651

Baseline HDRS-17 score

29.8 (4.2)

29.5 (4.4)

Mean difference: 0.30 (-0.97 to 1.57)

Welch’s t = 0.47

0.640

The ECT and ketamine groups had similar baseline demographic and clinical characteristics. Mean age was 39.4 (SD 11.2) years in the ECT group and 40.1 (SD 10.8) years in the ketamine group, with no statistically significant difference (mean difference -0.70 years, 95% CI -3.94 to 2.54; p=0.670). Women comprised 57.8% and 54.4% of the respective groups (p=0.652). Duration of the current episode, proportion experiencing a first depressive episode and proportion with previous treatment nonresponse were also comparable (p>0.05 for each comparison). Baseline HDRS-17 scores were 29.8 (SD 4.2) in the ECT group and 29.5 (SD 4.4) in the ketamine group (mean difference 0.30, 95% CI -0.97 to 1.57; p=0.640).

 

Table 2. change in depression severity from baseline to end of acute treatment

HDRS-17 measure

ECT (n=90)

Ketamine (n=90)

Between-group difference (95% CI)

Test statistic

p value

Baseline score

29.8 (4.2)

29.5 (4.4)

0.30 (-0.97 to 1.57)

Welch’s t = 0.47

0.640

End-of-treatment score

12.4 (5.8)

15.8 (6.0)

-3.40 (-5.14 to -1.66)

Welch’s t = -3.87

<0.001

Mean reduction from baseline

17.4 (6.0)

13.7 (6.3)

3.70 (1.89 to 5.51)

Welch’s t = 4.03

<0.001

Within-group change from baseline

17.4 (6.0)

13.7 (6.3)

—

Paired t = 27.51; 20.63, respectively

<0.001 in each group

Mean baseline HDRS-17 scores were similar in the ECT and ketamine groups (29.8 [SD 4.2] and 29.5 [SD 4.4], respectively; p=0.640). At the end of acute treatment, the mean score was 12.4 (SD 5.8) in the ECT group and 15.8 (SD 6.0) in the ketamine group. The between-group difference was -3.40 points (95% CI -5.14 to -1.66; p<0.001), indicating a lower end-of-treatment score in the ECT group. Mean reduction from baseline was 17.4 (SD 6.0) points with ECT and 13.7 (SD 6.3) points with ketamine; the difference in reduction was 3.70 points (95% CI 1.89 to 5.51; p<0.001). Scores decreased significantly from baseline within both groups (ECT paired t=27.51; ketamine paired t=20.63; p<0.001 for each).

 

Table 3. treatment response and remission rates

Outcome

ECT (n=90)

Ketamine (n=90)

RD (95% CI)

Test statistic

p value

Treatment response

63 (70.0%)

44 (48.9%)

21.1 percentage points (7.1 to 35.1)

χ² = 8.32

0.004

Remission

45 (50.0%)

30 (33.3%)

16.7 percentage points (2.5 to 30.9)

χ² = 5.14

0.023

The treatment response rate was 70.0% in the ECT group and 48.9% in the ketamine group. The risk difference was 21.1 percentage points (95% CI 7.1 to 35.1), and the between-group comparison was statistically significant (χ²=8.32; p=0.004). Remission was observed in 50.0% of the ECT group and 33.3% of the ketamine group, a risk difference of 16.7 percentage points (95% CI 2.5 to 30.9; χ²=5.14; p=0.023).

 

Table 4. treatment-related adverse effects

Adverse effect

ECT (n=90)

Ketamine (n=90)

RD (95% CI)

Test statistic

p value

Any recorded adverse effect

51 (56.7%)

47 (52.2%)

4.4 percentage points (-10.1 to 19.0)

χ² = 0.36

0.549

Memory complaint

28 (31.1%)

10 (11.1%)

20.0 percentage points (8.4 to 31.6)

χ² = 10.81

0.001

Headache

15 (16.7%)

17 (18.9%)

-2.2 percentage points (-13.4 to 8.9)

χ² = 0.15

0.697

Nausea

12 (13.3%)

16 (17.8%)

-4.4 percentage points (-15.0 to 6.1)

χ² = 0.68

0.411

Transient blood-pressure elevation

10 (11.1%)

22 (24.4%)

-13.3 percentage points (-24.3 to -2.3)

χ² = 5.47

0.019

Dissociative symptoms

3 (3.3%)

31 (34.4%)

-31.1 percentage points (-41.6 to -20.6)

χ² = 28.43

<0.001

Post-treatment confusion

19 (21.1%)

7 (7.8%)

13.3 percentage points (3.2 to 23.4)

χ² = 6.47

0.011

Muscle pain

18 (20.0%)

4 (4.4%)

15.6 percentage points (6.3 to 24.9)

χ² = 10.15

0.001

At least one recorded adverse effect was reported for 56.7% of the ECT group and 52.2% of the ketamine group; this difference was not statistically significant (p=0.549). Memory complaints, post-treatment confusion and muscle pain were more frequent in the ECT group, with statistically significant between-group differences. Transient blood-pressure elevation and dissociative symptoms were more frequent in the ketamine group, also with statistically significant differences. The frequencies of headache and nausea were similar between groups (p=0.697 and p=0.411, respectively).

DISCUSSION

Table 1. Baseline demographic and clinical characteristics

In the data, the ECT and ketamine groups were similar at baseline. There were no statistically significant differences in age, sex distribution, duration of the current depressive episode, first-episode status, previous treatment nonresponse or baseline HDRS-17 score. The baseline HDRS-17 scores were consistent with severe depressive symptoms in both groups. Sharma et al. (2020) also reported comparable baseline clinical and symptom scores in their small randomized comparison of ECT and ketamine [2]. The larger ELEKT-D trial likewise compared treatment groups with broadly similar baseline characteristics after randomisation [6]. Similar baseline measures are useful for interpreting subsequent score changes, but they do not establish that groups are equivalent on all relevant factors. If treatment allocation in the present study was based on clinical decisions rather than randomisation, differences in factors such as psychotic features, urgency of treatment, treatment preference or comorbidity could still influence outcomes. The results should therefore be interpreted as an association between treatment received and outcome, rather than proof that treatment alone caused any difference. Indian ECT guidance also emphasizes the importance of careful clinical assessment, informed consent and monitoring when ECT is used [1].

 

Table 2. Change in depression severity

In the results, mean HDRS-17 scores decreased in both groups, with a larger mean reduction in the ECT group than in the ketamine group. The between-group difference in reduction was statistically significant, and the end-of-treatment score was lower in the ECT group. This pattern is similar to Sharma et al. (2020), whose pilot study found greater symptom reduction with ECT over six treatment sessions, and to the KetECT trial, in which hospitalized patients assigned to ECT had greater remission and symptom reduction than those assigned to ketamine [2,5]. Kheirabadi et al. (2019), however, reported improvement in both groups without a statistically significant between-group difference; their trial was small, with 16 participants per group [3]. Findings also differed in the ELEKT-D trial: among adults with nonpsychotic treatment-resistant depression, ketamine was noninferior to ECT on the trial’s primary response outcome [6]. Jha et al. (2024) reported that relative improvement varied by clinical context and baseline severity, with very severe symptoms associated with earlier improvement on ECT in some analyses [7].

 

Meta-analyses have also reached differing conclusions. Rhee et al. (2022) and Menon et al. (2023) found evidence favouring ECT on some response, remission or symptom outcomes, while noting limitations in the small number and size of earlier trials [8,9]. Simoes Moreira et al. (2023) did not find a statistically significant overall difference in depression-score reduction [10]. These differences across studies may relate to patient selection, inpatient versus outpatient setting, psychotic features, treatment schedules, rating scales and the timing of outcome assessment. Thus, the score changes should not be treated as evidence that the same difference would occur in the actual study population.

 

Table 3. Treatment response and remission

The response and remission proportions were higher in the ECT group. The estimated response difference was 21.1 percentage points and the remission difference was 16.7 percentage points, with both comparisons reaching statistical significance in the data. Sharma et al. (2020) found higher response and remission proportions with ECT than with ketamine, although their sample was very small [2]. In the KetECT trial, remission occurred in 61% of participants receiving ECT and 45% receiving ketamine, also favouring ECT in that hospitalized population [5]. These findings are consistent with the direction of the results.

 

Other trials and pooled analyses have not shown a uniform ECT advantage. In the ELEKT-D trial, response was observed in 55.4% of the ketamine group and 41.2% of the ECT group, and ketamine met the study’s noninferiority criterion [6]. Kheirabadi et al. (2020), using intramuscular or oral ketamine in a small pilot comparison, reported improvement across treatment groups without a significant between-group difference [4]. The meta-analyses by Rhee et al. and Menon et al. found results that depended on which trials and analyses were included [8,9]. Liu et al. (2024) found a ranking that favoured ECT for some depression-severity outcomes, but not a consistent difference across all measures [11]. Differences in response definitions, remission cut-offs, treatment duration and participant characteristics limit direct comparison. In particular, the remission threshold of HDRS-17 ≤7 must match the definition used in the actual protocol and should be stated when reporting results.

 

Table 4. Treatment-related adverse effects

In the table, the proportion with any recorded adverse effect was similar between groups. The pattern showed more memory complaints, post-treatment confusion and muscle pain with ECT, while transient blood-pressure elevation and dissociative symptoms were more frequent with ketamine. Headache and nausea did not differ significantly in these data. This broadly resembles the distinct adverse-effect profiles described in comparative research: ketamine has been associated with dissociative or perceptual effects, while ECT has been associated with musculoskeletal symptoms and cognitive or memory complaints. In the ELEKT-D trial, musculoskeletal adverse effects were more common with ECT, whereas dissociation was more prominent with ketamine [6]. The KetECT trial also reported more dissociative symptoms and related perceptual effects with ketamine [5]. Meta-analyses have reported lower muscle-pain risk with ketamine and higher dissociative-symptom risk, although estimates vary and some comparisons are imprecise [8,10,12].

 

The difference in memory complaints should be interpreted cautiously. A reported memory complaint is not necessarily equivalent to a measured cognitive deficit; comparative studies have used different instruments and follow-up times. The ELEKT-D study reported a greater decline in delayed-recall performance with ECT during acute treatment, while pooled analyses have not found a consistent difference across all cognitive outcomes [6,8]. Research on ketamine given as an anaesthetic during ECT concerns a different comparison from ketamine administered as a separate antidepressant treatment. Trials and reviews of adjunctive ketamine during ECT have not established that it reliably prevents cognitive effects or improves overall outcomes [13–15]. Because the adverse-effect categories in Table 4 overlap and multiple unadjusted comparisons were performed, isolated statistically significant p values should be viewed as exploratory. Routine prospective recording and clear definitions of adverse events would be important in the actual study [1,16,17].

CONCLUSION

In the comparison of 180 patients with severe depression, both ECT and ketamine were associated with a reduction in HDRS-17 scores from baseline to the end of acute treatment. The ECT group showed a greater mean reduction and higher response and remission rates than the ketamine group. Adverse effects appeared to differ in type: memory complaints, post-treatment confusion and muscle pain were more frequent with ECT, whereas dissociative symptoms and transient blood-pressure elevation were more frequent with ketamine. These findings require confirmation using the actual study data. If treatment allocation was not randomised, the differences cannot be attributed to treatment alone. The results should be interpreted in the context of the study’s setting, patient characteristics, treatment protocols and follow-up period.

 

Limitations

The following limitations should be retained only if they apply to the completed study:

  • The tables currently contain values, so they cannot support conclusions about actual patients.
  • If conducted at a single tertiary care hospital, the findings may not represent patients treated in other settings.
  • If treatment was selected through routine clinical decision-making rather than randomisation, confounding by indication and differences in patient characteristics may have influenced the comparison.
  • Assessment only at the end of acute treatment would not establish the durability of response, relapse rates or longer-term safety.
  • HDRS-17 scores and adverse-effect reporting may have been affected by assessor or participant expectations if blinding was not feasible.
  • The adverse-effect categories may overlap, and multiple unadjusted comparisons increase the possibility of chance findings.
  • Differences in treatment dose, schedule, concomitant medication and criteria for response or remission could affect comparability.
  • If follow-up was incomplete, missing outcome data may have biased the results.
REFERENCES
  1. Thirthalli J, Sinha P, Sreeraj VS. Clinical practice guidelines for the use of electroconvulsive therapy. Indian J Psychiatry. 2023;65(2):258-269. doi:10.4103/indianjpsychiatry.indianjpsychiatry_491_22.
  2. Sharma RK, Kulkarni G, Kumar CN, Arumugham SS, Sudhir V, Mehta UM, et al. Antidepressant effects of ketamine and ECT: a pilot comparison. J Affect Disord. 2020;276:260-266. doi:10.1016/j.jad.2020.07.066.
  3. Kheirabadi G, Vafaie M, Kheirabadi D, Mirlouhi Z, Hajiannasab R. Comparative effect of intravenous ketamine and electroconvulsive therapy in major depression: a randomized controlled trial. Adv Biomed Res. 2019;8:25. doi:10.4103/abr.abr_166_18.
  4. Kheirabadi D, Kheirabadi GR, Mirlohi Z, Tarrahi MJ, Norbakhsh A. Comparison of rapid antidepressant and antisuicidal effects of intramuscular ketamine, oral ketamine, and electroconvulsive therapy in patients with major depressive disorder: a pilot study. J Clin Psychopharmacol. 2020;40:588-593.
  5. Ekstrand J, Fattah C, Persson M, Cheng T, Nordanskog P, Åkeson J, et al. Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority trial (KetECT). Int J Neuropsychopharmacol. 2022;25(5):339-349. doi:10.1093/ijnp/pyab088.
  6. Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023;388:2315-2325. doi:10.1056/NEJMoa2302399.
  7. Jha MK, Wilkinson ST, Krishnan K, Collins KA, Sanacora G, Murrough J, et al. Ketamine vs electroconvulsive therapy for treatment-resistant depression: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(6):e2417786. doi:10.1001/jamanetworkopen.2024.17786.
  8. Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, et al. Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis. JAMA Psychiatry. 2022;79(12):1162-1172. doi:10.1001/jamapsychiatry.2022.3352.
  9. Menon V, Varadharajan N, Faheem A, Andrade C. Ketamine vs electroconvulsive therapy for major depressive episode: a systematic review and meta-analysis. JAMA Psychiatry. 2023;80(6):639-642. doi:10.1001/jamapsychiatry.2023.0562.
  10. Simoes Moreira DA, Gauer LE, Teixeira G, da Silva ACF, Cavalcanti S, Quevedo J. Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: a systematic review and meta-analysis. J Affect Disord. 2023;330:227-238.
  11. Liu Y, Yang J, Liu Y. Ketamine and electroconvulsive therapy for severe depression: a network meta-analysis of efficacy and safety. J Psychiatr Res. 2024;175:218-226. doi:10.1016/j.jpsychires.2024.05.022.
  12. Ma Z, Wu F, Zheng W. Comparative efficacy and safety of ketamine versus electroconvulsive therapy in major depressive disorder: a meta-analysis of randomized controlled trials. Psychiatr Q. Published online February 18, 2025. doi:10.1007/s11126-025-10121-1.
  13. Ainsworth NJ, Sepehry AA, Vila-Rodriguez F. Effects of ketamine anesthesia on efficacy, tolerability, seizure response, and neurocognitive outcomes in electroconvulsive therapy: a comprehensive meta-analysis of double-blind randomized controlled trials. J ECT. 2020;36(2):94-105. doi:10.1097/YCT.0000000000000632.
  14. Li XM, Shi ZM, Wang PJ, Hu H. Effects of ketamine in electroconvulsive therapy for major depressive disorder: meta-analysis of randomised controlled trials. Gen Psychiatr. 2020;33(3):e100117. doi:10.1136/gpsych-2019-100117.
  15. Anderson IM, Blamire A, Branton T, Clark R, Downey D, Dunn G, et al. Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. Lancet Psychiatry. 2017;4(5):365-377. doi:10.1016/S2215-0366(17)30077-9.
  16. Ren L, Yu J, Zeng J, Wei K, Li P, Luo J, et al. Comparative efficacy and tolerability of different anesthetics in electroconvulsive therapy for major depressive disorder: a systematic review and network meta-analysis. J Psychiatr Res. 2024;171:116-125. doi:10.1016/j.jpsychires.2024.01.031.
  17. Elliott SI, Katz RB, Ostroff RB, Ansari M, Holmes SE, Sanacora G. Ketamine versus electroconvulsive therapy for the treatment of depression: a guide for clinicians. Focus (Am Psychiatr Publ). 2025;23(2):195-205. doi:10.1176/appi.focus.20240040.
Recommended Articles
Research Article
Substance Use Disorders and Aggressive Behaviour Among Individuals Referred for Medico-Legal Psychiatric Evaluation: A Cross-Sectional Study.
Published: 23/04/2024
Download PDF
Research Article
Comparative Evaluation of Cognitive Function in Patients with Schizophrenia Versus Bipolar Disorder: A Cross-Sectional Study
Published: 14/04/2024
Download PDF
Research Article
A Comparative Study of Psychiatric Morbidity in Patients with Substance Use Disorder and Non-Substance Users.
Published: 08/11/2024
Download PDF
Research Article
Association of Serum Albumin-to-Globulin Ratio with Left Ventricular Diastolic Dysfunction in Patients with Essential Hypertension: A Prospective Observational Study
...
Published: 29/10/2026
Download PDF
Chat on WhatsApp
Copyright © EJCM Publisher. All Rights Reserved.